For immunochemical detection of prostein
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Prostein (C-Term) Rabbit Monoclonal Antibody (Clone RM426)

Item No. 35318

Product Insert (PDF)
Technical Information
Synonyms
  • p501s
  • PCANAP6
  • Prostate Cancer-associated Protein 6
Immunogen
Peptide corresponding to the C-terminus of human Prostein
Clone Designation
RM426
Formulation (Request formulation change)
100 µl of protein A-affinity purified monoclonal antibody
Storage Buffer
PBS with 50% glycerol, 1% BSA, and 0.09% sodium azide
Host
Rabbit
Isotype
IgG
Applications
IHC
Cross Reactivity
(+) Prostein
Species Reactivity
(+) Human
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    100 µl

    $411

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Prostein, also known as prostate cancer-associated protein 6 (PCANAP6), is a prostate-specific protein encoded by SLC45A3 that is expressed in normal and malignant prostate tissues.1,2 It is composed of 11 transmembrane domains and localizes to the Golgi apparatus.3,4 Prostein mRNA and protein expression is increased by androgen stimulation in LNCaP prostate cancer cells, and prostein translation is reduced by miRNA-126* in the same model.1,5 It has been used as a biomarker for prostate cancer and to determine the origin of metastatic tumors.6 Reduced prostein expression is associated with SLC45A3-ERG gene fusions and reduced recurrence-free survival time in patients with prostate cancer.7 Cayman's Prostein (C-Term) Rabbit Monoclonal Antibody (Clone RM426) can be used for immunohistochemistry (IHC).

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Xu, J., Kalos, M., Stolk, J.A., et al. Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res. 61(4), 1563-1568 (2001).

    2. Kalos, M., Askaa, J., Hylander, B.L., et al. Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate 60(3), 246-256 (2004).

    3. Pin, E., Henjes, F., Hong, M.-G., et al. Identification of a novel autoimmune peptide epitope of prostein in prostate cancer. J. Proteome Res. 16(1), 204-216 (2017).

    4. Kristiansen, I., Stephan, C., Jung, K., et al. Sensitivity of HOXB13 as a diagnostic immunohistochemical marker of prostatic origin in prostate cancer metastases: Comparison to PSA, prostein, androgen receptor, ERG, NKX3.1, PSAP, and PSMA. Int. J. Mol. Sci. 18(6), 1151 (2017).

    5. Musiyenko, A., Bitko, V., and Barik, S. Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells. J. Mol. Med. (Berl.) 86(3), 313-322 (2008).

    6. Queisser, A., Hagedorn, S.A., Braun, M., et al. Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer. Mod. Pathol. 28(1), 138-145 (2015).

    7. Perner, S., Rupp, N.J., Braun, M., et al. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course. Int. J. Cancer 132(4), 807-812 (2013).